N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents

D. Impellizzeri, R. Di Paola, Akbar Ahmad, R. Crupi, I. Paterniti, M. Campolo, G. Bruschetta, S. Clemente, E. Esposito, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

Abstract

Experimental autoimmune encephalomyelitis in rodents (EAE) is an accepted in vivo model for immunopathogenic mechanisms underlying multiple sclerosis (MS) and tests possible treatment options because it mimics many of the disease patterns. The current treatments for delaying MS progression include cytostatic, immunomodulatory drugs such as mitoxantrone, cyclophosphamide (CY), biological agents such as interferon (IFN)-beta, natalizumab and random polymer glatiramer acetate. Unfortunately, all of these compounds have potentially serious side effects, some require systemic administration, and the biological agents are costly and immunogenic, causing response failure during prolonged treatment. With this aim in mind, the purpose of the current research was to examine the effects of endogenous substances such as N-palmitoylethanolamine (PEA). PEA is an endogenous fatty acid amide belonging to the family of the N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in both central and sensory nervous systems as well as immune cells. The effect of PEA daily administered was investigated in rats and mice developing EAE. A multidisciplinary approach was employed to study behavior and biochemical parameters. In our study we found that PEA counteracts the clinical course and pathology of monophasic EAE in myelin basic protein-immunized Lewis rats and the progression of EAE induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein. Our results show that PEA treatment had a beneficial effect on the two different EAE models.

Original languageEnglish (US)
Pages (from-to)373-388
Number of pages16
JournalEuropean Journal of Inflammation
Volume12
Issue number2
StatePublished - 2014
Externally publishedYes

Fingerprint

Autoimmune Experimental Encephalomyelitis
Rodentia
Biological Factors
Multiple Sclerosis
Myelin-Oligodendrocyte Glycoprotein
Mitoxantrone
Clinical Pathology
Myelin Basic Protein
Interferon-beta
Cytostatic Agents
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Inbred C57BL Mouse
Amides
Cyclophosphamide
Immunization
Polymers
Fatty Acids
Central Nervous System
palmidrol

Keywords

  • Behavior
  • Experimental autoimmune encephalomyelitis
  • Lethanolamine
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Impellizzeri, D., Di Paola, R., Ahmad, A., Crupi, R., Paterniti, I., Campolo, M., ... Cuzzocrea, S. (2014). N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents. European Journal of Inflammation, 12(2), 373-388.

N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents. / Impellizzeri, D.; Di Paola, R.; Ahmad, Akbar; Crupi, R.; Paterniti, I.; Campolo, M.; Bruschetta, G.; Clemente, S.; Esposito, E.; Cuzzocrea, Salvatore.

In: European Journal of Inflammation, Vol. 12, No. 2, 2014, p. 373-388.

Research output: Contribution to journalArticle

Impellizzeri, D, Di Paola, R, Ahmad, A, Crupi, R, Paterniti, I, Campolo, M, Bruschetta, G, Clemente, S, Esposito, E & Cuzzocrea, S 2014, 'N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents', European Journal of Inflammation, vol. 12, no. 2, pp. 373-388.
Impellizzeri, D. ; Di Paola, R. ; Ahmad, Akbar ; Crupi, R. ; Paterniti, I. ; Campolo, M. ; Bruschetta, G. ; Clemente, S. ; Esposito, E. ; Cuzzocrea, Salvatore. / N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents. In: European Journal of Inflammation. 2014 ; Vol. 12, No. 2. pp. 373-388.
@article{0b154c14767f46c497636a83ad56f778,
title = "N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents",
abstract = "Experimental autoimmune encephalomyelitis in rodents (EAE) is an accepted in vivo model for immunopathogenic mechanisms underlying multiple sclerosis (MS) and tests possible treatment options because it mimics many of the disease patterns. The current treatments for delaying MS progression include cytostatic, immunomodulatory drugs such as mitoxantrone, cyclophosphamide (CY), biological agents such as interferon (IFN)-beta, natalizumab and random polymer glatiramer acetate. Unfortunately, all of these compounds have potentially serious side effects, some require systemic administration, and the biological agents are costly and immunogenic, causing response failure during prolonged treatment. With this aim in mind, the purpose of the current research was to examine the effects of endogenous substances such as N-palmitoylethanolamine (PEA). PEA is an endogenous fatty acid amide belonging to the family of the N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in both central and sensory nervous systems as well as immune cells. The effect of PEA daily administered was investigated in rats and mice developing EAE. A multidisciplinary approach was employed to study behavior and biochemical parameters. In our study we found that PEA counteracts the clinical course and pathology of monophasic EAE in myelin basic protein-immunized Lewis rats and the progression of EAE induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein. Our results show that PEA treatment had a beneficial effect on the two different EAE models.",
keywords = "Behavior, Experimental autoimmune encephalomyelitis, Lethanolamine, Multiple sclerosis",
author = "D. Impellizzeri and {Di Paola}, R. and Akbar Ahmad and R. Crupi and I. Paterniti and M. Campolo and G. Bruschetta and S. Clemente and E. Esposito and Salvatore Cuzzocrea",
year = "2014",
language = "English (US)",
volume = "12",
pages = "373--388",
journal = "European Journal of Inflammation",
issn = "1721-727X",
publisher = "Biolife",
number = "2",

}

TY - JOUR

T1 - N-palmitoylethanolamine administration ameliorates the clinical manifestation and progression of experimental autoimmune encephalomyelitis in rodents

AU - Impellizzeri, D.

AU - Di Paola, R.

AU - Ahmad, Akbar

AU - Crupi, R.

AU - Paterniti, I.

AU - Campolo, M.

AU - Bruschetta, G.

AU - Clemente, S.

AU - Esposito, E.

AU - Cuzzocrea, Salvatore

PY - 2014

Y1 - 2014

N2 - Experimental autoimmune encephalomyelitis in rodents (EAE) is an accepted in vivo model for immunopathogenic mechanisms underlying multiple sclerosis (MS) and tests possible treatment options because it mimics many of the disease patterns. The current treatments for delaying MS progression include cytostatic, immunomodulatory drugs such as mitoxantrone, cyclophosphamide (CY), biological agents such as interferon (IFN)-beta, natalizumab and random polymer glatiramer acetate. Unfortunately, all of these compounds have potentially serious side effects, some require systemic administration, and the biological agents are costly and immunogenic, causing response failure during prolonged treatment. With this aim in mind, the purpose of the current research was to examine the effects of endogenous substances such as N-palmitoylethanolamine (PEA). PEA is an endogenous fatty acid amide belonging to the family of the N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in both central and sensory nervous systems as well as immune cells. The effect of PEA daily administered was investigated in rats and mice developing EAE. A multidisciplinary approach was employed to study behavior and biochemical parameters. In our study we found that PEA counteracts the clinical course and pathology of monophasic EAE in myelin basic protein-immunized Lewis rats and the progression of EAE induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein. Our results show that PEA treatment had a beneficial effect on the two different EAE models.

AB - Experimental autoimmune encephalomyelitis in rodents (EAE) is an accepted in vivo model for immunopathogenic mechanisms underlying multiple sclerosis (MS) and tests possible treatment options because it mimics many of the disease patterns. The current treatments for delaying MS progression include cytostatic, immunomodulatory drugs such as mitoxantrone, cyclophosphamide (CY), biological agents such as interferon (IFN)-beta, natalizumab and random polymer glatiramer acetate. Unfortunately, all of these compounds have potentially serious side effects, some require systemic administration, and the biological agents are costly and immunogenic, causing response failure during prolonged treatment. With this aim in mind, the purpose of the current research was to examine the effects of endogenous substances such as N-palmitoylethanolamine (PEA). PEA is an endogenous fatty acid amide belonging to the family of the N-acylethanolamines (NAEs). Recently, several studies demonstrated that PEA is an important analgesic, anti-inflammatory and neuroprotective mediator, acting at several molecular targets in both central and sensory nervous systems as well as immune cells. The effect of PEA daily administered was investigated in rats and mice developing EAE. A multidisciplinary approach was employed to study behavior and biochemical parameters. In our study we found that PEA counteracts the clinical course and pathology of monophasic EAE in myelin basic protein-immunized Lewis rats and the progression of EAE induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein. Our results show that PEA treatment had a beneficial effect on the two different EAE models.

KW - Behavior

KW - Experimental autoimmune encephalomyelitis

KW - Lethanolamine

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84905853843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905853843&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84905853843

VL - 12

SP - 373

EP - 388

JO - European Journal of Inflammation

JF - European Journal of Inflammation

SN - 1721-727X

IS - 2

ER -